Citations

Clear

23 citation(s) found for "Tompkins, C -A A".

A19-10 Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 3 PROSERA Trial
Ghofrani, H A, Mclaughlin, V V, Meyer, G Bohns, Benza, R L, Channick, R N, Chin, K M, Frantz, R P, Hemnes, A R, Howard, L S, Zamanian, R T, Kopeć, G, Skride, A, Jerjes-Sánchez, C, Lescano, A J, Subías, M P Escribano, White, R J, Zamudio, T Pulido, Perna, E R, Rosenkranz, S, Badagliacca, R, Scelsi, L, Lima, M A, Sulica, R, Miller, C, Al-Hiti, H, Campos, F, Zagolin, M, Roscigno, R F, Mottola, D, Aranda, R, Cravets, M, Tompkins, C -A A, Parsley, E, Elman, E, Zisman, L S, Vachiery, J L, Sitbon, O, Ghofrani, H A, McLaughlin, Vallerie V. , Meyer, Gisela Martina Bohns , Benza, Raymond L. , Channick, R N, Chin, K M, Frantz, Robert P. , Hemnes, A R, Howard, L S, Zamanian, R.T., Kopeć, Grzegorz , Skride, Andris , Jerjes‐Sánchez, Carlos , Subias, M P Escribano, White, R. James , Perna, Eduardo , Rosenkranz, S, Badagliacca, Roberto , Scelsi, Laura , Sulica, Roxana, Miller, Chad E., Al‐Hiti, Hikmet, Roscigno, Robert F., Mottola, David, Aranda, R, Cravets, Matt , Parsley, Ed, Elman, Erin, Zisman, Lawrence S. , Vachiéry, Jean‐Luc , Sitbon, Olivier

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 22, 2026 | Volume: 212 | Issue: Supplement_2 | Pages: No page available

10.1093/ajrccm/aamag286.279 Get It

Abstract Rationale Seralutinib is an investigational, first-in-class tyrosine kinase inhibitor designed for inhalation and selective for PDGFRα, PDGFRβ, CSF1R, and cKIT, targeting proliferation, inflammation, and fibrosis ─ three core drivers of pulmonary vascular remodeling in PAH. The phase 2 TORREY trial of seralutinib added to standard-of-care treatment in adults with PAH WHO FC II or III met its primary endpoint of a statistically significant reduction in pulmonary vascular resistance (PVR) vs. placebo at 24 weeks. Methods PROSERA (NCT05934526), a phase 3, randomized, double-blind, placebo-controlled, multicenter trial, evaluated the efficacy and safety of inhaled seralutinib in PAH patients treated for up to 48 weeks. Eligible patients (WHO Group 1 PH, FC II or III; REVEAL Lite 2 Risk Score ≥5 or NT-proBNP ≥300 ng/L or PVR ≥800 dyne•s/cm5) on standard background therapy were randomized 1:1 to seralutinib 90 mg or placebo delivered by dry powder inhaler twice daily. The primary endpoint was change in six-minute walk distance (6MWD) from baseline to week 24 in the seralutinib treatment group vs. placebo. Key secondary endpoints included: time to clinical worsening (TTCW), proportion of patients with clinical improvement at week 24, change in NT-proBNP from baseline to week 24, and proportion of patients with ≥1-point decrease from baseline in REVEAL Lite 2 Risk Score at week 24. Safety endpoints included incidence of treatment-emergent adverse events (TEAEs) and serious TEAEs (SAEs). Patients who completed blinded treatment could be eligible to participate in an open-label extension study. Preliminary Blinded Results 390 patients were randomized at 132 sites worldwide. At baseline, mean age was 50.0 years. PAH etiologies included 61.0% idiopathic, 9.7% heritable, and 22.3% associated with connective tissue disease. 25.6% of patients were WHO FC II and 74.4% FC III. Mean time from diagnosis was TBD years. Most patients were receiving 2 (39.2%) or ≥ 3 (54.6%) PAH medications, 29.2% were receiving parenteral prostacyclin. Baseline PVR was 798.4 dyne•s/cm5, 6MWD was 373.7 m, and NT-proBNP was 986.8 ng/L. The difference in 6MWD from baseline to week 24 between seralutinib and placebo was TBD [SD] m (p=TBD). Secondary endpoints of TTCW, clinical improvement, NT-proBNP, and REVEAL Lite 2 Risk Score will be reported. The most common AEs were TBD (x%) and TBD (y%). SAEs and discontinuations related to AE will be reported. Conclusions The PROSERA study demonstrates⋯ [to be updated following unblinding of the data]. Funding Gossamer Bio, Inc. This abstract is funded by: Gossamer Bio, Inc.
The Efficacy of Bracing in Nonoperative Care of Medial Femoral Condyle Osteochondritis Dissecans: A Study From the Research in Osteochondritis Dissecans of the Knee (ROCK) Study Group
Group, The ROCK, Nissen, Carl W. , Albright, Jay C. , Anderson, Christian N. , Busch, Michael T., Carey, James L. , Carlson, Cathy , Carsen, Sasha , Crepeau, Allison, Edmonds, Eric W. , Ellermann, Jutta , Ellis, Henry B. , Erickson, John B. , Godin, Jonathan , Ganley, Theodore J. , Grimm, Nathan L. , Heyworth, Benton E. , Po, James Hui Hoi, Kocher, Mininder S., Koehler, Ryan, Latz, Kevin, Loveland, Dustin M., Lyon, Roger M., Meenen, Norbert M., Milewski, Matthew D., Myer, Gregory D., Nelson, Bradley J., Nepple, Jeffrey, Nguyen, Jie C. , Paterno, Mark V. , Pennock, Andrew T. , Perkins, Crystal A. , Polousky, John D. , Riley, Pat, Saluan, Paul, Shea, Kevin G., Tompkins, Marc , Wall, Eric J. , Willimon, S. Clifton , Wright, Rick W. , Shea, Kevin G. , Edmonds, Eric W , Ellis, Henry B , Fabricant, Peter D , Ganley, Theodore J , Green, Daniel W , Heyworth, Benton E , Krych, Aaron J , Pace, J Lee , Pennock, Andrew T , Perkins, Crystal A , Tompkins, Marc A , Nissen, Carl , Busch, Michael T., Carlson, Cathy, Chambers, Henry G. , Godin, Jonathan, Hui, James Hoi Po, Kocher, Mininder Singh , Koehler, Ryan J. , Krych, Aaron J. , Lyon, Roger, Meenen, N. M., Milewski, Matthew D. , Myer, Gregory D. , Nelson, Bradley J. , Nepple, Jeffrey J. , Weiss, Jennifer M., Wilson, Philip L. , Kostyun, Regina O.

Mayo Clinic

The American Journal of Sports Medicine | April 15, 2026 | Volume: 54 | Issue: 6 | Pages: 1415-1422

10.1177/03635465261429407 | PMID 41981903 Get It

Background: Stable osteochondritis dissecans (OCD) lesions are primarily treated nonoperatively. Nonoperative treatment includes several recommendations, including the use of an unloader brace. However, little is known about the clinical effectiveness of unloader bracing and its influence on OCD healing, return to sports, and patient-reported outcomes (PROs). The purpose of this investigation was to evaluate the impact of unloader bracing on patients with stable medial femoral condyle (MFC) OCD lesions treated nonoperatively. Purpose: To investigate the influence of valgus unloader bracing on the success of treating stable MFC OCD with nonoperative treatment strategies. Study Design: Cohort study; Level of evidence, 2. Methods: The authors used a prospective cohort of patients receiving nonoperative care for stable MFC knee OCD lesions. The primary variable of interest was the efficacy of bracing. The primary outcomes were transition from nonoperative care to surgical intervention, return-to-play (RTP) clearance, and PROs. Bivariate testing was used to determine if there were differences between groups. Chi-square testing was used to determine if there were differences in rates of transition to surgery by group. The timing of the transition by each group was assessed using a Wilcoxon rank-sum test, given the nonparametric nature of the data. Kaplan-Meier survival analysis was used to calculate time at risk, incidence rate, and survival times for each group. Results: A total of 185 knees (bracing group: 123 [66.5%] knees; no-bracing group: 62 [33.5%] knees) were analyzed. Overall, 142 (76.8%) knees were successfully treated nonoperatively. Transition to surgery occurred in 43 (23.2%) knees. There were no differences in transition to surgery by groups, with no differences seen by group. Of the knees that did not transition to surgical care, 65 (71.4%) in the bracing group and 38 (74.5%) in the no-bracing group received RTP clearance ( P = .693). PRO scores were similar between the 2 groups at the time of RTP clearance. Conclusion: The inclusion of an unloader brace in the nonoperative treatment for stable MFC OCD lesions did not decrease the likelihood of patients undergoing surgical intervention or improve their PRO scores at the time of RTP clearance. Registration: NCT02771496 (ClinicalTrials.gov identifier).
Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers
Najia, Mohamad , Jha, Deepak Kumar , Zhang, Cheng , Kubaczka, Caroline , Markel, Arianna , Li, Christopher , Morris, Vivian Gunn, Tompkins, Allison, Hensch, Luca, Qin, Yue , Huang, Yu-Chung , Marunde, Matthew R. , Vaidya, Anup , Gillespie, Zachary B , Shi, Yang , Li, Hu , Daley, George Q. , Najia, Mohamad Ali , Jha, Deepak K , North, Trista E , Keogh, Michael-Christopher , Schlaeger, Thorsten M , Shipp, Margaret Ann , Blainey, Paul C , Daley, George Q , Laurent, Benoît , Li, Christopher, Morris, Vivian, Chapuy, Bjoern , Morse, Michael, Howard, Sarah A. , Domínguez, Daniel

Mayo Clinic

No container title available | February 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.01.31.635709 | PMID 39975048 Get It

ABSTRACT Genes involved in the regulation of chromatin structure are frequently disrupted in cancer, contributing to an aberrant transcriptome and phenotypic plasticity. Yet, therapeutics targeting mutant forms of chromatin-modifying enzymes have yielded only modest clinical utility, underscoring the difficulty of targeting the epigenomic underpinnings of aberrant gene regulatory networks. Here, we sought to identify novel epigenetic vulnerabilities in diffuse large B-cell lymphoma (DLBCL). Through phenotypic screens and biochemical analysis, we demonstrated that inhibition of the H3K9 demethylases KDM4A and KDM4C elicits potent, subtype-agnostic cytotoxicity by antagonizing transcriptional networks associated with B-cell identity and epigenetically rewiring heterochromatin. KDM4 demethylases associated with the KRAB zinc finger ZNF587, and their enzymatic inhibition led to DNA replication stress and DNA damage-induced cGAS-STING activation. Broad surveys of transcriptional data from patients also revealed KDM4 family dysregulation in several other cancer types. To explore this potential therapeutic avenue, we performed high-throughput small molecule screens with H3K9me3 nucleosome substrates and identified novel KDM4 demethylase inhibitors. AI-guided protein-ligand binding predictions suggested diverse modes of action for various small molecule hits. Our findings underscore the relevance of targeting fundamental transcriptional and epigenetic mechanisms for anti-cancer therapy. HIGHLIGHTS Phenotypic screens identified JIB-04 as a potent anti-cancer agent for multiple subtypes of diffuse large B-cell lymphoma JIB-04 binds and inhibits KDM4 demethylases resulting in epigenomic rewiring of heterochromatin KDM4 demethylases cooperate with KRAB zinc fingers to limit DNA replication stress, and KDM4 inhibition instigates DNA-damage and cGAS-STING activation in several human cancers High-throughput small molecule screens with semi-synthetic nucleosome substrates and AI-guided molecular docking simulations identify novel KDM4 inhibitors
Which Osteochondritis Dissecans Lesions Will Heal Nonoperatively? An Application of Machine Learning to the ROCK Prospective Cohort
Johnstone, T, Espiritu, Joseph , Tompkins, Marc , Milewski, Matthew D. , Nissen, Carl W. , Shea, Kevin G. , Group:, the ROCK, Egger, Anthony C. , Anderson, Christian N. , Pace, James Lee, Polousky, John D. , Ellemann, Jutta, Meenen, N. M., Ellis, Henry B. , Carey, James, Nissen, Carl , Espiritu, Joseph, Group:, the ROCK, Nelson, Bradley J. , Pace, James Lee, Edmonds, Eric W. , Fabricant, Peter D , Krych, Aaron J. , Myer, Gregory D. , Kocher, Mininder Singh , Carey, James

Mayo Clinic

Orthopaedic Journal of Sports Medicine | December 16, 2024 | Volume: 12 | Issue: 12 | Pages: No page available

10.1177/23259671241297145 | PMID 39697601 Get It

Background: There are limited evidence-based guidelines to predict which osteochondritis dissecans (OCD) lesions will heal with nonoperative treatment. Purpose: To train a set of classification algorithms to predict nonoperative OCD healing while identifying new clinically meaningful predictors. Study Design: Case-control study; Level of evidence, 3. Methods: Patients with OCD of the knee with open physes undergoing nonoperative management were prospectively queried from the Research on OCD of the Knee (ROCK) cohort ( https://kneeocd.org ) in April 2022. Patients were included if they met the study criteria for nonoperative treatment success or failure. Nonoperative treatment success was defined as complete healing on magnetic resonance imaging (MRI) and total return to sports participation. Failure was defined as the crossover from nonoperative management to surgery at any point at or beyond the 3-month follow-up. If a patient did not meet one of these criteria, they were not included. Normalized lesion size, lesion location, patient characteristics, and symptoms were used as clinically relevant predictors. Results: A total of 64 patients were included, of whom 24 (37.5%) patients successfully healed with nonoperative management. Multivariate logistic regression revealed that a 1% increase in normalized lesion width was associated with an increase in the likelihood of nonoperative failure (odds ratio [OR], 1.41 [95% CI, 1.17-1.81]; P < .01). By contrast, lesions in the posterior sagittal zone (OR, 0.08 [95% CI, 0.009-0.43]; P < .01) or the medial-most coronal zone (for lesions of the medial femoral) and lateral-most coronal zone (for lesions of the lateral femoral condyle) on MRI (OR, 0.05 [95% CI, 0.004-0.44]; P < .01) were associated with a decrease in the likelihood of nonoperative treatment failure. Support vector machines had a cross-validated area under the receiver operating characteristic curve of 0.89 and a classification accuracy of 83.3%. Conclusion: Lesion location in the posterior aspect of the condyle on sagittal MRI and lesion location in the medial-most or lateral-most locations on coronal MRI were identified as statistically significant predictors of increased nonoperative treatment success on multivariate analysis. Machine learning models can predict which OCD lesions will heal with nonoperative management with superior accuracy compared with previously published models.
A Simple Clinical Predictive Model for Arthroscopic Mobility of Osteochondritis Dissecans Lesions of the Knee
Milewski, Matthew D., Milewski, Matthew D., Miller, Patricia E., Gossman, Emma C. , Coene, Ryan P. , Tompkins, Marc , Anderson, Christian N. , Bauer, Kathryn, Busch, Michael T., Carey, James L. , Ellermann, Jutta , Ellis, Henry B. , Erickson, John , Ganley, Theodore J. , Heyworth, Benton E. , Latz, Kevin, Lyon, Roger, Mayer, Stephanie W. , Milewski, Matthew D. , Milewski, Matthew D., Miller, Patricia E., Nepple, Jeffrey J. , Nguyen, Jie C. , Nissen, Carl W. , Paterno, Mark V. , Pennock, Andrew T. , Perkins, Crystal A. , Polousky, John D. , Saluan, Paul, Shea, Kevin G. , Wall, Eric J. , Willimon, Clifton, Wilson, Philip L., Wright, Rick W. , Zbojniewicz, Andy, Myer, Gregory D , Milewski, Matthew D., Milewski, Matthew D., Miller, Patricia E., Carsen, Sasha , Chambers, Henry G. , Edmonds, Eric W. , Fabricant, Peter D , Green, Daniel W , Hui, James Hoi Po , Kocher, Mininder Singh , Krych, Aaron J. , Milewski, Matthew D., Miller, Patricia E., Nelson, Bradley J. , Pace, J Lee , Weiss, Jennifer M., Wilson, Philip L. , Myer, Gregory D.

Mayo Clinic

The American Journal of Sports Medicine | November 25, 2024 | Volume: 52 | Issue: 14 | Pages: 3543-3550

10.1177/03635465241296133 | PMID 39584729 Get It

Background: Osteochondritis dissecans (OCD) of the knee is a focal idiopathic alteration of subchondral bone and/or its precursor with risk for instability and disruption of adjacent cartilage. Treatment options focused on preventing premature osteoarthritis vary depending on multiple patient and lesion characteristics, including lesion mobility. Purpose: To differentiate lesion mobility before arthroscopy using a multivariable model that includes patient demographic characteristics and physical examination findings. Study Design: Cohort study (Diagnosis); Level of evidence, 2. Methods: Demographic, preoperative physical examination, and radiographic data were collected from a multicenter national prospective cohort of patients with OCD of the knee. Inclusion criteria included patients <19 years of age and patients with arthroscopically confirmed mobility status based on the Research on Osteochondritis Dissecans of the Knee arthroscopy classification. Multivariable logistic regression analysis using stepwise model selection was used to determine factors associated with the likelihood of a mobile versus an immobile lesion. A 75% partition of the data was used for model training, and 25% was used as a validation cohort. Quantitative model fit statistics were computed using the holdout data, including sensitivity, specificity, and the area under the receiver operating characteristic curve (AUC), along with the corresponding 95% CI. Results: A total of 407 patients in the prospective cohort met inclusion criteria, and 62% were male. The mean ± SD age was 13.7 ± 2.2 years, height 161.8 ± 5.3 cm, and weight 59.2 ± 42.2 kg. Arthroscopic evaluation yielded 235 immobile and 172 mobile lesions. Multivariable analysis determined that the best model to predict lesion mobility included chronologic age ≥14 years ( P < .001), effusion on physical examination ( P < .001), and any loss of range of motion on physical examination ( P = .07), while controlling for male sex ( P = .38) and weight >54.4 kg ( P = .12). In the 25% holdout validation sample (n = 102), a sensitivity of 83%, a specificity of 82%, and an AUC of 0.89 (95% CI, 0.82-0.95) were achieved with these predictive factors. Conclusion: Age, effusion, and loss of motion can predict knee OCD lesion mobility at the time of arthroscopy. Education about lesion mobility can help with surgical planning and patient and family counseling.
Advanced Neuromuscular Training Differentially Changes Performance on Visuomotor Reaction Tests and Single-leg Hop Tests in Patients with ACL Reconstruction
Chmielewski, Terese L. , Obermeier, Michael, Meierbachtol, Adam , Jenkins, Asher, Sikka, Robby , Tompkins, Marc , Obermeier, Michael, Stuart, Michael J.

Mayo Clinic

International Journal of Sports Physical Therapy | November 2, 2024 | Volume: 19 | Issue: 11 | Pages: No page available

10.26603/001c.124807 | PMID 39502551 Get It

Background Advanced neuromuscular training prepares patients with anterior cruciate ligament reconstruction (ACLR) for sport participation. Return-to-sport testing often includes single-leg hop tests, yet combining motor and cognitive tasks (i.e., dual-task) might reveal neurocognitive reliance. Purpose/Hypothesis This study examined changes in performance on visuomotor reactions tests and single-leg hop tests following advanced neuromuscular training in patients with ACLR. The hypothesis was that performance would improve less on reaction tests than on single-leg hop tests. Study Design Quasi experimental, Pretest-Posttest Methods Twenty-five patients with ACLR (11 males) completed 10 sessions of advanced neuromuscular training and pre-and post-training testing. Reaction tests outcomes were from a platform and visual display. The double-leg reaction test involved touching target dots with either leg for 20 seconds; correct touches and errors were recorded. The single-leg reaction test involved hopping on the test leg to 10 target dots; hop time and errors were recorded. Single-leg hop tests included forward, triple, crossover triple, and timed hop; limb symmetry index was recorded. Effect sizes were calculated for corrected touches on the double-leg reaction test, surgical side hop time on the single-leg reaction test, and surgical side hop distance or time on single-leg hop tests. Results Correct touches on the double-leg reaction test significantly increased from pre- to post-training (20.4 +/- 4.3 vs. 23.9 +/- 2.8, p<0.001). Hop time on the single-leg reaction test significantly decreased from pre- to post-training (Surgical leg 13.2 vs. 12.3 seconds, non-surgical leg 13.0 vs. 12.1 seconds, p=0.003). Mean errors did not significantly change on either reaction test (p> 0.05). Cohens d effect sizes in descending order was single-leg hop tests (d=0.9 to 1.3), double-leg reaction test (d=0.9), and single-leg reaction test (d=0.5). Conclusion Motor performance improved after advanced neuromuscular training, but the effect size was less on visuomotor reaction tests than single-leg hop tests. The results suggest persistence of neurocognitive reliance after ACLR and a need for more dual-task challenges in training. Level of Evidence 3
Pediatric Knee Arthroscopy: The Basics of Pediatric Knee Arthroscopy from a Collection of Pediatric Sports Medicine Experts
Kirby, Julia, Johnson, B. Lamar , Millewski, Matt, Shea, Kevin G. , Beck, Jennifer J. , Milbrandt, Todd A. , Pace, Lee, Vandenberg, Curt, Tompkins, Marc , Gamble, James G. , Ganley, Ted, Ellis, Henry B. , Milbrandt, Todd, Ellis, Henry B , Millewski, Matthew, Wilson, Philip L. , Schmitz, Matthew R. , Edmonds, Eric W. , Yen, Yi‐Meng

Mayo Clinic

Video Journal of Sports Medicine | August 1, 2023 | Volume: 3 | Issue: 4 | Pages: No page available

10.1177/26350254231168160 | PMID 40308682 Get It

Background/Objective: To share technical pearls of a basic knee arthroscopy in a pediatric patient by presenting tips and tricks used by experienced pediatric arthroscopists. Indications: Knee arthroscopy is a common procedure performed by most orthopedic surgeons. However, technical considerations and equipment should be considered before performing this procedure in a pediatric patient. This video provides information on indications, equipment, and patient positioning, as well as outlining a systematic approach to diagnostic arthroscopy and pertinent pediatric anatomy. Discussion/Conclusion: This video provides an excellent overview as well as specific pathology-dependent considerations for the inexperienced orthopedic surgeon, or the orthopedic surgeon who rarely performs knee arthroscopy. Patient Consent Disclosure Statement: The author(s) attests that consent has been obtained from any patient(s) appearing in this publication. If the individual may be identifiable, the author(s) has included a statement of release or other written form of approval from the patient(s) with this submission for publication.
Massive left atrial thrombus evades multimodality imaging as a myxoma in a bicaval heart transplant recipient
Shou, Benjamin L. , Halub, Meghan E, Zhou, Alice L. , Tompkins, Bryon A. , Choi, Chun Woo

Mayo Clinic

Journal of Cardiac Surgery | July 5, 2022 | Volume: 37 | Issue: 9 | Pages: 2884-2887

10.1111/jocs.16708 | PMID 35789119 Get It

Abstract Intracardiac masses are an extremely rare and poorly described complication following a bicaval heart transplantation. We describe the case of an asymptomatic 62‐year‐old male with a large left atrial mass found incidentally on transthoracic echocardiography 6 years post‐transplant. A battery of additional imaging tests was ordered including transesophageal echocardiography, 18 F‐fluorodeoxyglucose positron emission tomography/computed tomography, and T1 and T2 magnetic resonance imaging. Although imaging biomarkers were generally nonspecific, the mass was most consistent with a cardiac myxoma. However, intraoperative findings confirmed by pathology revealed a massive organizing thrombus. The patient had an uneventful recovery after surgical removal of the mass. Our case highlights a very rare phenomenon in heart transplant recipients which remains a unique diagnostic challenge even with current advances in imaging.
Accuracy of Case-Based Seroprevalence of SARS-CoV-2 Antibodies in Maricopa County, Arizona
Jehn, Megan, Pandit, Urvashi, Sabin, Susanna, Tompkins, Camila, White, Jessica, Kaleta, Erin, Dale, Ariella P., Ross, Heather M., McCullough, J. Mac, Pepin, Susan, Kenny, Katherine, Sanborn, Heidi, Heywood, Natalie, Schnall, Amy H., Lant, Timothy, Sunenshine, Rebecca, Jehn, Megan , Pandit, Urvashi, Sabin, Susanna J. , Tompkins, Camila, White, Jessica, Kaleta, Erin, Dale, Ariella P., Ross, Heather M., McCullough, J. Mac, Pepin, Susan, Kenny, Katherine, Sanborn, Heidi, Heywood, Natalie, Schnall, Amy H., Lant, Timothy, Sunenshine, Rebecca

Mayo Clinic

American Journal of Public Health | December 22, 2021 | Volume: 112 | Issue: 1 | Pages: 38-42

10.2105/ajph.2021.306568 | PMID 34936397 Get It

We conducted a community seroprevalence survey in Arizona, from September 12 to October 1, 2020, to determine the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We used the seroprevalence estimate to predict SARS-CoV-2 infections in the jurisdiction by applying the adjusted seroprevalence to the county’s population. The estimated community seroprevalence of SARS-CoV-2 infections was 4.3 times greater (95% confidence interval = 2.2, 7.5) than the number of reported cases. Field surveys with representative sampling provide data that may help fill in gaps in traditional public health reporting. (Am J Public Health. 2022;112(1):38–42. https://doi.org/10.2105/AJPH.2021.306568 )